A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity.
about
Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogensRecent advances towards tuberculosis control: vaccines and biomarkersAdenovirus vectors for gene therapy, vaccination and cancer gene therapyAdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human PrimatesProtection Induced by Simultaneous Subcutaneous and Endobronchial Vaccination with BCG/BCG and BCG/Adenovirus Expressing Antigen 85A against Mycobacterium bovis in CattleCapsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approachNovel vaccination strategies against tuberculosis.Age at Mycobacterium bovis BCG Priming Has Limited Impact on Anti-Tuberculosis Immunity Boosted by Respiratory Mucosal AdHu5Ag85A Immunization in a Murine ModelBoosting BCG-primed mice with chimeric DNA vaccine HG856A induces potent multifunctional T cell responses and enhanced protection against Mycobacterium tuberculosis.DNA immunization of Mycobacterium tuberculosis resuscitation-promoting factor B elicits polyfunctional CD8(+) T cell responses.Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.The influence of delivery vectors on HIV vaccine efficacyFirst-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy.The sero-prevalence of anti-adenovirus 5 neutralizing antibodies is independent of a chronic hepatitis B carrier state in ChinaHelicobacter hepaticus infection in BALB/c mice abolishes subunit-vaccine-induced protection against M. tuberculosis.Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety ConsiderationsA Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates.Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.Immunization with Ty21a live oral typhoid vaccine elicits crossreactive multifunctional CD8+ T-cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A, and S. Paratyphi B in humansAntigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform.Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85AImmediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells.Novel vaccine approaches for protection against intracellular pathogens.The BCG replacement vaccine VPM1002: from drawing board to clinical trial.Aerosol immunisation for TB: matching route of vaccination to route of infectionCD8 T cells and Mycobacterium tuberculosis infection.Developments in Viral Vector-Based Vaccines.Adenoviral vector-based strategies against infectious disease and cancer.Analysis of purified wild type and mutant adenovirus particles by SILAC based quantitative proteomics.Induction of an Immune-Protective T-Cell Repertoire With Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans.A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.Transient CD4+ T Cell Depletion Results in Delayed Development of Functional Vaccine-Elicited Antibody Responses.Expression and role of VLA-1 in resident memory CD8 T cell responses to respiratory mucosal viral-vectored immunization against tuberculosis.Adenoviral type 35 and 26 vectors with a bidirectional expression cassette in the E1 region show an improved genetic stability profile and potent transgene-specific immune response.CXCR3 Signaling Is Required for Restricted Homing of Parenteral Tuberculosis Vaccine-Induced T Cells to Both the Lung Parenchyma and Airway.Enhancement of Antituberculosis Immunity in a Humanized Model System by a Novel Virus-Vectored Respiratory Mucosal Vaccine.Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses.
P2860
Q26750912-CEEC741A-4C65-4B6D-99DD-4564AD702401Q26859739-C069C9CA-C673-445C-9F52-9CBCEC8EA172Q27001601-57F7EEB2-6406-4748-B46E-7BEE912CEB34Q27300923-022DBAC4-2F84-4F48-A5C3-F8A249CC8208Q27346370-F2B21FBF-24DE-40B7-9FDD-7EFD82E9432AQ28607775-A0C62500-1E28-4E72-B4F6-BCF465BED2E9Q30363188-FE5FF191-C909-4796-825C-85243788A64EQ30375962-9268B194-D531-452A-99F2-BD547B0F862EQ30376072-9B7029B4-FBEA-434D-8AE7-5D4C3A3B7BC7Q33850516-4B0C259E-098F-43C0-AC43-0EDE88E1D7C9Q33992101-D3423FC7-E92E-40C7-920C-C18698FC98B5Q34077543-C2FD9E7A-FB94-49C3-AAD1-DE8DB271A971Q34209026-CFB2D1D5-8F0D-46B8-A4A9-9D06F3115BDFQ34991437-FADA3969-7A53-43BC-A7DC-E23D409087CCQ35009081-43F299C9-FC6D-4A1A-91F5-A1FF74327914Q35204923-681AA2B6-8CA2-46F9-861A-A1ECEB32A6F8Q35573126-E3332696-70B4-4F77-BCBF-506154E758AAQ35826779-D7BD91B1-0FDB-4898-8B69-C9CA5F12551FQ35849628-EC38C240-200A-428D-AF05-EAD72D97F423Q35887146-3B527384-D9AB-4412-ABFD-3467121F765DQ36166784-936C96B6-BE12-4547-A2EB-BB0D0F75CE6EQ36330007-A24E0D81-8B77-4290-9E7E-D897A9A6249BQ36347381-946B880A-C918-40E5-88D5-4D68C377E386Q36369598-2E67A1F1-EA1C-4537-A9A5-50AC684FA7CDQ37189696-EA0B1C25-1998-4F15-AC2C-7E124DC619AFQ38194389-D6CAD5F7-579E-4A4D-9A8C-213251B6ABCDQ38202181-A093A8EC-53D3-461E-A762-D2B3AE268A17Q38338183-F23F6606-542D-4D65-AABA-03CCCCB1EB3FQ38445065-ADC04C50-1717-4E12-B186-C84925ECA3A2Q38582090-4DCE00B4-5E4A-44DB-B05B-D036462AE123Q38814885-D6B852CB-DFDC-4E4F-ABEA-013827303155Q38968416-4C395376-581E-4C2B-8DD0-A2E6265E46F3Q39323110-C9D3CF1E-2410-4158-9E11-258E6D1552C0Q39441716-29B10775-9397-4ADC-970A-4479784B5A3AQ40005891-37D9BCFF-6E83-474F-99F5-C75BE2E6231FQ40069778-5AAFF613-5550-492F-9ECD-2413C9D75B3AQ40080155-1530C648-D0A2-4B8D-92A8-DE13CF0FE769Q40085228-A2D8B5A1-CA5E-454C-834D-2A943F138474Q40190981-7B599EF2-36C7-4AD0-AE24-DAEA0F69A645Q40256121-E00874F6-B82B-4599-9032-4AA619E367C8
P2860
A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A human type 5 adenovirus-base ...... ting anti-adenovirus immunity.
@en
A human type 5 adenovirus-base ...... ting anti-adenovirus immunity.
@nl
type
label
A human type 5 adenovirus-base ...... ting anti-adenovirus immunity.
@en
A human type 5 adenovirus-base ...... ting anti-adenovirus immunity.
@nl
prefLabel
A human type 5 adenovirus-base ...... ting anti-adenovirus immunity.
@en
A human type 5 adenovirus-base ...... ting anti-adenovirus immunity.
@nl
P2093
P2860
P1476
A human type 5 adenovirus-base ...... ting anti-adenovirus immunity.
@en
P2093
Anna Zganiacz
Armando Heriazon
Daniela Damjanovic
Fiona Smaill
Jack Gauldie
Jemila Hamid
Laura Puri
Mangalakumari Jeyanathan
P2860
P304
P356
10.1126/SCITRANSLMED.3006843
P407
P577
2013-10-01T00:00:00Z